Get the Stockscreener App
15.44
1.97%
-0.31
Benitec Biopharma Inc stock is traded at $15.44, with a volume of 212.65K.
It is down -1.97% in the last 24 hours and up +13.53% over the past month.
Benitec Biopharma Inc is a clinical-stage biotechnology company focused on the advancement of novel genetic medicines. Its technology has the potential to provide a one-shot cure for a wide range of diseases that are addressed by strict ongoing treatment regimens or that have no effective treatment or only palliative care options. The Company is developing a silence and replace-based therapeutic (BB-301) for the treatment of Oculopharyngeal Muscular Dystrophy (OPMD), a chronic, life threatening genetic disorder.
See More
Previous Close:
$15.75
Open:
$15.95
24h Volume:
212.65K
Relative Volume:
4.00
Market Cap:
$424.73M
Revenue:
$59,000
Net Income/Loss:
$-21.81M
P/E Ratio:
-1.4098
EPS:
-10.9518
Net Cash Flow:
$-18.07M
1W Performance:
-4.57%
1M Performance:
+13.53%
6M Performance:
+20.91%
1Y Performance:
+106.14%
1-Day Range:
$14.93
$16.08
1-Week Range:
$14.91
$17.11
52-Week Range:
$5.742
$17.15
Benitec Biopharma Inc Stock (BNTC) Company Profile
Name
Benitec Biopharma Inc
Sector
Industry
Phone
(510) 780-0819
Address
3940 TRUST WAY, HAYWARD, CA
Compare BNTC with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
BNTC
Benitec Biopharma Inc
|
15.44 | 424.73M | 59,000 | -21.81M | -18.07M | -10.95 |
|
VRTX
Vertex Pharmaceuticals Inc
|
441.99 | 115.95B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
508.86 | 56.52B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
308.71 | 39.44B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
540.71 | 35.14B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
254.09 | 28.51B | 3.81B | -644.79M | -669.77M | -6.24 |
Benitec Biopharma Inc Stock (BNTC) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-16-24 | Initiated | H.C. Wainwright | Buy |
| Dec-13-24 | Initiated | Robert W. Baird | Outperform |
| Oct-16-24 | Initiated | Oppenheimer | Outperform |
| Sep-12-24 | Initiated | Guggenheim | Buy |
| Jul-22-24 | Initiated | Leerink Partners | Outperform |
| Jun-13-24 | Initiated | Piper Sandler | Overweight |
| Oct-05-20 | Downgrade | Ladenburg Thalmann | Buy → Neutral |
| Apr-20-20 | Initiated | Ladenburg Thalmann | Buy |
| Feb-26-16 | Downgrade | Maxim Group | Buy → Hold |
| Dec-31-15 | Reiterated | Maxim Group | Buy |
| Sep-16-15 | Reiterated | Maxim Group | Buy |
View All
Benitec Biopharma Inc Stock (BNTC) Latest News
GAMMA Investing LLC Grows Stake in Benitec Biopharma Inc. (NASDAQ:BNTC) - Defense World
Benitec Biopharma (BNTC) is on the Move, Here's Why the Trend Could be Sustainable - Nasdaq
(BNTC) Trading Report - news.stocktradersdaily.com
Wall Street Analysts See a 65.98% Upside in Benitec Biopharma (BNTC): Can the Stock Really Move This High? - Yahoo Finance
Benitec Biopharma Inc. (NASDAQ:BNTC) Position Boosted by Ameriprise Financial Inc. - Defense World
Is Benitec Biopharma (BNTC) Outperforming Other Medical Stocks This Year? - Yahoo Finance
Form 424B3 Benitec Biopharma Inc. - StreetInsider
Northern Trust Corp Grows Stock Holdings in Benitec Biopharma Inc. (NASDAQ:BNTC) - Defense World
Recent Price Trend in Benitec Biopharma (BNTC) is Your Friend, Here's Why - Yahoo Finance
Benitec Biopharma Inc. (NASDAQ:BNTC) Given Consensus Recommendation of “Buy” by Brokerages - Defense World
Benitec Biopharma’s SWOT analysis: gene therapy stock shows promise amid trials - Investing.com Nigeria
(BNTC) Investment Report - news.stocktradersdaily.com
Benitec Biopharma (BNTC) Files to Sell 900K Shares - GuruFocus
Benitec Biopharma (BNTC) Proposes Sale of 900K Common Shares | B - GuruFocus
Benitec Biopharma (BNTC) Proposes Sale of 900K Common Shares | BNTC Stock News - GuruFocus
FY2025 EPS Forecast for Benitec Biopharma Raised by Analyst - Defense World
Wall Street Analysts Think Benitec Biopharma (BNTC) Could Surge 83.91%: Read This Before Placing a Bet - Yahoo Finance
Benitec Biopharma (NASDAQ:BNTC) Receives “Buy” Rating from HC Wainwright - Defense World
Benitec Biopharma (BNTC) Receives Buy Rating from HC Wainwright & Co. | BNTC Stock News - GuruFocus
Are Medical Stocks Lagging Benitec Biopharma (BNTC) This Year? - Yahoo Finance
Leerink Partnrs Issues Optimistic Forecast for BNTC Earnings - Defense World
Benitec Biopharma (NASDAQ:BNTC) Earns Market Outperform Rating from JMP Securities - Defense World
(BNTC) Trading Signals - news.stocktradersdaily.com
Benitec Biopharma (BNTC) Analyst Rating Update from JMP Securities | BNTC Stock News - GuruFocus
Benitec stock holds $20 target, Market Outperform rating - Investing.com
Benitec stock holds $20 target, Market Outperform rating By Investing.com - Investing.com India
Benitec (BNTC) Advances BB-301 Treatment for OPMD with Promising Clinical Progress | BNTC Stock News - GuruFocus
Benitec Biopharma Inc reports results for the quarter ended March 31Earnings Summary - TradingView
Benitec Biopharma Q3 Operating Income USD -10.2 Million - marketscreener.com
Benitec Biopharma Releases Third Quarter 2025 Financial Results - GuruFocus
Benitec Biopharma reports Q3 EPS (24c) vs. (23c) last year - TipRanks
Benitec Biopharma Inc. SEC 10-Q Report - TradingView
Benitec Biopharma Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended March 31, 2025 - marketscreener.com
Benitec Biopharma (BNTC) Expected to Announce Quarterly Earnings on Monday - Defense World
How To Trade (BNTC) - news.stocktradersdaily.com
Benitec Biopharma (BNTC) Is a Great Choice for 'Trend' Investors, Here's Why - Yahoo Finance
Benitec Biopharma Inc. (NASDAQ:BNTC) Receives Consensus Recommendation of “Buy” from Analysts - Defense World
Is Benitec Biopharma (BNTC) Stock Outpacing Its Medical Peers This Year? - Yahoo Finance
Benitec Biopharma Inc. (NASDAQ:BNTC) Shares Purchased by Geode Capital Management LLC - Defense World
Wall Street Analysts Believe Benitec Biopharma (BNTC) Could Rally 84.96%: Here's is How to Trade - MSN
What Makes Benitec Biopharma (BNTC) a New Buy Stock - Yahoo Finance
(BNTC) Long Term Investment Analysis - news.stocktradersdaily.com
Are Medical Stocks Lagging Ascendis Pharma (ASND) This Year? - Yahoo Finance
Benitec Biopharma: An Under-The-Radar And Undervalued Gene Therapy Developer - Seeking Alpha
Benitec Biopharma Inc Stock (BNTC) Financials Data
Revenue
Net Income
Cash Flow
EPS
3.63%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):